Michael A. Jakupec

16.1k total citations · 5 hit papers
228 papers, 14.1k citations indexed

About

Michael A. Jakupec is a scholar working on Oncology, Organic Chemistry and Molecular Biology. According to data from OpenAlex, Michael A. Jakupec has authored 228 papers receiving a total of 14.1k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Oncology, 143 papers in Organic Chemistry and 52 papers in Molecular Biology. Recurrent topics in Michael A. Jakupec's work include Metal complexes synthesis and properties (174 papers), Ferrocene Chemistry and Applications (75 papers) and Lanthanide and Transition Metal Complexes (38 papers). Michael A. Jakupec is often cited by papers focused on Metal complexes synthesis and properties (174 papers), Ferrocene Chemistry and Applications (75 papers) and Lanthanide and Transition Metal Complexes (38 papers). Michael A. Jakupec collaborates with scholars based in Austria, Germany and Slovakia. Michael A. Jakupec's co-authors include Bernhard K. Keppler, M. Galanski, Christian G. Hartinger, Vladimir B. Arion, Walter Berger, Petra Heffeter, Haralabos Zorbas, Stefanie Zorbas‐Seifried, Christian R. Kowol and Alexander Roller and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Michael A. Jakupec

226 papers receiving 13.9k citations

Hit Papers

From bench to bedside – preclinical and early clinical de... 2005 2026 2012 2019 2006 2007 2008 2005 2014 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)
    2006 860 citations Michael A. Jakupec, Bernhard K. Keppler et al. profile →
  2. Antitumour metal compounds: more than theme and variations
    2007 761 citations Michael A. Jakupec, M. Galanski et al. Dalton Transactions profile →
  3. KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
    2008 732 citations Michael A. Jakupec, Walter Berger et al. profile →
  4. Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches
    2005 631 citations M. Galanski, Michael A. Jakupec et al. Current Medicinal Chemistry profile →
  5. NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
    2014 583 citations Petra Heffeter, Michael A. Jakupec et al. Chemical Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael A. Jakupec Austria 62 10.5k 8.7k 3.4k 2.2k 2.0k 228 14.1k
Christian G. Hartinger New Zealand 72 12.2k 1.2× 11.1k 1.3× 4.2k 1.2× 2.5k 1.1× 2.5k 1.3× 275 17.6k
Luigi Messori Italy 68 8.9k 0.8× 6.7k 0.8× 4.9k 1.4× 2.6k 1.2× 1.9k 1.0× 388 15.9k
Giovanni Natile Italy 50 6.1k 0.6× 5.4k 0.6× 2.9k 0.9× 2.1k 1.0× 1.5k 0.7× 356 10.3k
Ingo Ott Germany 54 6.5k 0.6× 8.1k 0.9× 2.6k 0.8× 1.7k 0.8× 1.4k 0.7× 205 11.8k
Angela Casini Italy 75 7.5k 0.7× 11.3k 1.3× 8.6k 2.5× 2.3k 1.0× 2.0k 1.0× 296 19.6k
Nicholas P. Farrell United States 58 7.9k 0.7× 5.8k 0.7× 4.8k 1.4× 1.5k 0.7× 1.0k 0.5× 294 10.9k
Abraha Habtemariam United Kingdom 56 6.0k 0.6× 6.1k 0.7× 1.9k 0.6× 1.8k 0.8× 2.0k 1.0× 127 9.2k
M. Galanski Austria 45 5.3k 0.5× 4.3k 0.5× 1.9k 0.6× 1.4k 0.6× 947 0.5× 193 8.0k
Vladimir B. Arion Austria 52 5.9k 0.6× 5.7k 0.6× 1.6k 0.5× 1.7k 0.7× 2.2k 1.1× 248 9.0k
Liang‐Nian Ji China 62 5.9k 0.6× 4.4k 0.5× 4.5k 1.3× 3.8k 1.7× 1.5k 0.8× 250 12.1k

Countries citing papers authored by Michael A. Jakupec

Since Specialization
Citations

This map shows the geographic impact of Michael A. Jakupec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael A. Jakupec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael A. Jakupec more than expected).

Fields of papers citing papers by Michael A. Jakupec

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael A. Jakupec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael A. Jakupec. The network helps show where Michael A. Jakupec may publish in the future.

Co-authorship network of co-authors of Michael A. Jakupec

This figure shows the co-authorship network connecting the top 25 collaborators of Michael A. Jakupec. A scholar is included among the top collaborators of Michael A. Jakupec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael A. Jakupec. Michael A. Jakupec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Dömötör, Orsolya, Michaela Hejl, Alexander Roller, et al.. (2024). Investigating the anticancer potential of 4-phenylthiazole derived Ru(ii) and Os(ii) metalacycles. Dalton Transactions. 53(12). 5567–5579. 6 indexed citations
4.
5.
Maier, Thomas, Michaela Hejl, Klaudia Cseh, et al.. (2023). Not the usual suspect – an unexpected organometallic product during the synthesis of cytotoxic platinum(ii) complexes. Dalton Transactions. 52(44). 16326–16335. 1 indexed citations
6.
Cseh, Klaudia, Andreas Schweikert, Alexander Roller, et al.. (2023). Anticancer Tungstenocenes with a Diverse Set of (O,O–), (O,S–) and (O,N–) Chelates—A Detailed Biological Study Using an Improved Evaluation via 3D Spheroid Models. Pharmaceutics. 15(7). 1875–1875. 1 indexed citations
7.
Cseh, Klaudia, Michaela Hejl, Benjamin Neuditschko, et al.. (2022). Highly Cytotoxic Molybdenocenes with Strong Metabolic Effects Inhibit Tumour Growth in Mice. Chemistry - A European Journal. 29(4). e202202648–e202202648. 3 indexed citations
8.
Westermayr, Julia, Klaudia Cseh, Michaela Hejl, et al.. (2021). Tridentate 3-Substituted Naphthoquinone Ruthenium Arene Complexes: Synthesis, Characterization, Aqueous Behavior, and Theoretical and Biological Studies. Inorganic Chemistry. 60(13). 9805–9819. 15 indexed citations
9.
Meier, Samuel M., Klaudia Cseh, Sarah Theiner, et al.. (2020). Plecstatin-1 induces an immunogenic cell death signature in colorectal tumour spheroids. Metallomics. 12(12). 2121–2133. 38 indexed citations
10.
Hejl, Michaela, Anton A. Legin, Andreas Schweikert, et al.. (2020). Synthesis, Modification, and Biological Evaluation of a Library of Novel Water‐Soluble Thiopyridone‐Based Organometallic Complexes and Their Unexpected (Biological) Behavior. Chemistry - A European Journal. 26(24). 5419–5433. 13 indexed citations
11.
Hejl, Michaela, Michael A. Jakupec, Sarah Theiner, et al.. (2020). IntroducingN-,P-, andS-donor leaving groups: an investigation of the chemical and biological properties of ruthenium, rhodium and iridium thiopyridone piano stool complexes. Dalton Transactions. 49(44). 15693–15711. 12 indexed citations
12.
Cseh, Klaudia, Alexander Roller, Michaela Hejl, et al.. (2019). The First Anticancer Tris(pyrazolyl)borate Molybdenum(IV) Complexes: Tested in Vitro and in Vivo—A Comparison of O,O‐, S,O‐, and N,N‐Chelate Effects. Chemistry - A European Journal. 26(10). 2211–2221. 10 indexed citations
13.
Roller, Alexander, Michaela Hejl, Michael A. Jakupec, et al.. (2019). Naphthoquinones of natural origin: Aqueous chemistry and coordination to half-sandwich organometallic cations. Journal of Organometallic Chemistry. 907. 121070–121070. 7 indexed citations
14.
Kiakos, Konstantinos, Giorgia Del Favero, Nathalie Harrer, et al.. (2019). First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro. Metallomics. 11(6). 1044–1048. 115 indexed citations
15.
Hejl, Michaela, Matthias H. M. Klose, Alexander Roller, et al.. (2018). N- and S-donor leaving groups in triazole-based ruthena(ii)cycles: potent anticancer activity, selective activation, and mode of action studies. Dalton Transactions. 47(13). 4625–4638. 19 indexed citations
16.
Dömötör, Orsolya, Alexander Roller, Michaela Hejl, et al.. (2017). Comparative equilibrium and structural studies of new pentamethylcyclopentadienyl rhodium complexes bearing (O,N) donor bidentate ligands. Journal of Organometallic Chemistry. 846. 287–295. 11 indexed citations
17.
Bolotin, Dmitrii S., Marina Ya. Demakova, Anton A. Legin, et al.. (2017). Amidoxime platinum(ii) complexes: pH-dependent highly selective generation and cytotoxic activity. New Journal of Chemistry. 41(14). 6840–6848. 10 indexed citations
18.
Hejl, Michaela, Alexander Roller, Matthias H. M. Klose, et al.. (2016). Introducing the 4-Phenyl-1,2,3-Triazole Moiety as a Versatile Scaffold for the Development of Cytotoxic Ruthenium(II) and Osmium(II) Arene Cyclometalates. Inorganic Chemistry. 56(1). 528–541. 55 indexed citations
19.
Galanski, M., Michael A. Jakupec, & Bernhard K. Keppler. (2005). Update of the Preclinical Situation of Anticancer Platinum Complexes: Novel Design Strategies and Innovative Analytical Approaches. Current Medicinal Chemistry. 12(18). 2075–2094. 631 indexed citations breakdown →
20.
Galanski, M., V.B. Arion, Michael A. Jakupec, & Bernhard K. Keppler. (2003). Recent Developments in the Field of Tumor-Inhibiting Metal Complexes. Current Pharmaceutical Design. 9(25). 2078–2089. 452 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christian G. Hartinger Breakdown of academic impact, for papers by Luigi Messori Breakdown of academic impact, for papers by Giovanni Natile Breakdown of academic impact, for papers by Ingo Ott Breakdown of academic impact, for papers by Angela Casini Breakdown of academic impact, for papers by Nicholas P. Farrell Breakdown of academic impact, for papers by Abraha Habtemariam Breakdown of academic impact, for papers by M. Galanski Breakdown of academic impact, for papers by Vladimir B. Arion Breakdown of academic impact, for papers by Liang‐Nian Ji
Rankless by CCL
2026